Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ThermoDox Study for Liver Cancer Treatment Continues

By Drug Discovery Trends Editor | July 13, 2011

An independent data monitoring committee (DMC) for Celsion’s multinational, double-blind, placebo-controlled Phase III clinical study of ThermoDox in combination with radiofrequency ablation (RFA) for primary liver cancer has completed a review of 535 randomized patients and unanimously recommended that the study continue according to protocol.

Celsion also announced that enrollment in the Heat study has reached 98% of the 600 patients necessary to ensure that its primary end point, progression free survival, can be achieved with statistical significance.
 
The study’s design and statistical plan incorporate a pre-planned interim efficacy analysis by the DMC—after patient enrollment is complete and 190 progression-free survival (PFS) events are realized in the study population—with the intent of evaluating safety, efficacy, and futility to determine if there is overwhelming evidence of clinical benefit or a low probability of treatment success to continue, modify or terminate the study. Completion of the interim analysis is expected by the end of the third quarter of 2011.
 
“For the vast majority of patients, progression in unresectable primary liver cancer treated using conventional radiofrequency ablation therapy occurs within one year, underscoring the urgent need for more effective treatment in first-line care,” says Michael H. Tardugno, president and chief executive officer of Celsion.

“ThermoDox is designed to concentrate doxorubicin in the margins surrounding the tumor, activating only in the presence of heat. Our data strongly indicate that the result is an increase treatment area which may extend the cure rate of RFA to larger, more locally advanced tumors.  The Heat study is poised to confirm this potential, with final data read out for the primary outcome measure expected in mid-2012.”
 
 
 Release Date: July 11, 2011
Source: Celsion 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE